Ignota Labs Acquires Kronos’s Clinical Pipeline

Ignota Labs Acquires Kronos’s Clinical Pipeline

CAMBRIDGE, England--(BUSINESS WIRE)--Oct 6, 2025-

Former $3.5bn-valued Kronos has assets acquired by Ignota Labs

Cambridge-based AI drug turnaround company Ignota Labs has acquired the full clinical asset portfolio of former unicorn Kronos. The once high-flying MedTech, which was listed on the Nasdaq Stock Exchange, saw its valuation peak at $3.5 billion before its collapse earlier this year. Kronos had advanced two key programmes – istisociclib, a CDK9 inhibitor, and entospletinib and lanraplenib, both SYK inhibitors – into phase 2 trials before halting o…